Novavax, Inc. (NVAX), and vaccine manufacturing major Serum Institute of India Pvt. Ltd. (SII), said on Friday that the Thailand Food and Drug Administration or Thai FDA has granted emergency use authorization or EUA for Novavax' protein-based vaccine against Covid-19 in Thailand.
With this move, the Thai regulator has granted EUA for Covovax /Recombinant Spike Protein of SARS-CoV-2 Virus 5 mcg to stimulate immunity against SARS-CoV-2 to prevent Covid-19 in adults 18 years age or above.
The vaccine, also known as NVX-CoV2373, is made and sold by Serum Institute under the brand name Covovax.
The Thai FDA's decision follows the totality of preclinical, manufacturing, and clinical trial data submitted for review.
This includes two pivotal Phase 3 clinical trials including PREVENT-19, which enrolled around 30,000 participants aged 18 years and older in the U.S. and Mexico and a trial with almost 15,000 participants in the U.K.
Covovax has received emergency use listing from the WHO, as well as EUA in India, Indonesia, the Philippines, and Bangladesh.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.